Haemonetics Co. (NYSE:HAE) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. cut its position in Haemonetics Co. (NYSE:HAE) by 10.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,354 shares of the medical instruments supplier’s stock after selling 5,810 shares during the period. Harbor Capital Advisors Inc.’s holdings in Haemonetics were worth $3,932,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its position in Haemonetics by 3.3% in the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $304,000 after acquiring an additional 117 shares during the period. Vontobel Holding Ltd. grew its holdings in shares of Haemonetics by 3.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after purchasing an additional 180 shares during the period. Arizona State Retirement System increased its position in shares of Haemonetics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after purchasing an additional 272 shares during the last quarter. Keene & Associates Inc. raised its holdings in Haemonetics by 3.0% in the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock valued at $818,000 after buying an additional 298 shares during the period. Finally, Versor Investments LP lifted its position in Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.8 %

Shares of NYSE:HAE opened at $76.70 on Friday. The company has a market cap of $3.85 billion, a PE ratio of 31.83, a P/E/G ratio of 1.26 and a beta of 0.41. The company’s 50 day moving average is $82.45 and its two-hundred day moving average is $80.52. Haemonetics Co. has a 52 week low of $70.25 and a 52 week high of $97.97. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. During the same period in the previous year, the business earned $0.99 EPS. Haemonetics’s revenue for the quarter was up 8.6% on a year-over-year basis. Equities analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. Barrington Research restated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research note on Wednesday, December 4th. CL King started coverage on Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.